摘要
目的分析MEK/ERK信号通路在上皮性卵巢癌顺铂耐药中的参与作用,为临床治疗提供参考。方法分析郑州大学第一附属医院2015年2月—2017年8月期间诊治的92例卵巢癌顺铂耐药患者(观察组)的临床资料,检测患者MEK/ERK(extracellular regulated protein kinases)信号转导通路相关蛋白的表达。以同期未发生顺铂耐药的卵巢癌患者(对照组)90例为对照。结果卵巢癌顺铂耐药患者血清中MEK/ERK信号通路蛋白Ras、Raf、MEK、ERK1、ERK2及PI3K和AKT蛋白的表达水平明显高于对照组,且差异存在统计学意义(均P<0.05);观察组患者血清中Bcl2(B-cell lymphoma-2)蛋白的表达水平明显高于对照组,细胞凋亡蛋白Bax(Bcl-2 associated X protein,BAX)和caspase-9(cysteinyl aspartate specific proteinase 9)水平明显低于对照组,且差异存在统计学意义(均P<0.05)。结论卵巢癌顺铂耐药过程可能与体内MEK/ERK信号通路及PI3K和AKT蛋白的异常表达有关。
Objective The present research tried to explore the involvement of MEK/ERK signaling pathway in cisplatin- resistance in ovarian cancer. Methods 92 eases of eisplatin-resistanee ovarian cancer patients in our hospital from Feb- ruary, 2015 to August, 2017 were enrolled in this part. The expression of MEK/ERK signaling pathway related proteins was detected by ELISA. Ninety cases of ovarian cancer patients without cisplatin-resistance at the same period were taken as control. Results The result revealed that the expression of MEK/ERK signaling pathway related proteins Ras, Raf, MEK and ERK1/2 as well as PI3K/AKT proteins were increased in observation group than control （P 〈 0.05 ）. At the mean time, the Bcl2 were increased （ P 〈 0.05 ） while the expression of Bax and caspase-9 were decreased （ P 〈 0.05 ） in observation group than control with statistical differences. Conclusion MEK/ERK signaling pathway as well as ab- normal expression of PI3K and AKT are involved in cisplatin-resistance in ovarian cancer patients.
作者
张冬雅
郭红军
冯巍
邱海峰
ZHANG Dong-ya;GUO Hong-jun;FENG Wei;et al(Department of Obstetrics and Gynecology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, Chin)
出处
《中华全科医学》
2018年第9期1490-1492,共3页
Chinese Journal of General Practice
基金
2015年度河南省医学科技攻关计划项目(201503009)
